Anthrogen

Y Combinator Summer 2024 · Biotech & pharma · North America

What it sells

We work on generalizable tools for the next era of biotech.

Funding history and coverage

Round dateStageAmountInvestorsSource
—Y Combinator Summer 2024—Y Combinatorycombinator.com

Profiles summarize public reporting and company websites. Business-model notes are MaxBC's reading of that material, not confirmed facts; unknowns are left blank rather than guessed. Updated 2026-10-11.

More startups in Biotech & pharma

  1. OMass Therapeutics

    OMass Therapeutics, based at ARC Oxford (UK); site sections cover science, technology, pipeline and news.

    Series C · €275M · 2026-10-16Biotech & pharmaEurope
  2. RxActuator

    RxActuator makes a pet-hospital-grade wearable infusion pump (Mini-Infuser) for pain management and drug delivery during pet recovery at home.

  3. SWAN Genomics

    UNSW Sydney spinout developing a DNA sequencing platform based on a plasmonic nanoantenna that reads native DNA molecules without amplification.

    $6M · 2026-10-15Biotech & pharmaAsia
  4. Souffle Therapeutics

    Develops oligonucleotide (siRNA) therapies designed to reach and enter the specific cells that drive disease, starting with programs in FSHD muscular dystrophy and heart failure.

  5. OlsAro

    AgTech company developing climate-resilient cereal seed varieties (salt-tolerant wheat, heat-resistant and nitrogen-efficient seeds) using its SeedAX biotech platform for trait…

    Seed · $5.5M · 2026-10-14Biotech & pharmaEurope
  6. NuSynth

    NuSynth is an R&D-led process innovation platform that redesigns synthesis routes for complex chemistry (pharmaceutical and electronic chemicals) using fewer steps, safer…

    Seed · ₹36.5 Cr · 2026-10-13Biotech & pharmaAsia

All startups in this market →